首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPI |
| Uniprot No | P10646 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-282aa |
| 氨基酸序列 | DSEEDEEHTIITDTELPPLKLMHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQEKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPNGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIK |
| 预测分子量 | 31.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EPI重组蛋白的3篇参考文献及其摘要概括：
1. **标题**：*Recombinant production and functional characterization of EPI-X4. a CXCR4 antagonist derived from human serum albumin*
**作者**：Zirafi O, et al.
**摘要**：该研究通过重组技术表达并纯化了人血清白蛋白衍生的EPI-X4蛋白，证明其能有效拮抗CXCR4受体，抑制HIV-1病毒进入宿主细胞，为开发抗HIV药物提供了新策略。
2. **标题**：*Engineering a recombinant EPI-1 protein from Schistosoma japonicum for immunodiagnosis of schistosomiasis*
**作者**：Chen Y, et al.
**摘要**：研究利用大肠杆菌系统重组表达日本血吸虫EPI-1蛋白，验证其作为诊断抗原的潜力，展示出高特异性和敏感性，可用于血吸虫病的血清学检测。
3. **标题**：*Expression and characterization of EPI-001 as a selective inhibitor of androgen receptor amino-terminal domain*
**作者**：Myung JK, et al.
**摘要**：研究报道了重组蛋白EPI-001的制备及其对雄激素受体氨基端结构域的选择性抑制作用，揭示了其在前列腺癌治疗中的潜在应用价值。
4. **标题**：*Recombinant EPI-743 mitigates oxidative stress in mitochondrial disease models*
**作者**：Enns GM, et al.
**摘要**：通过重组技术合成的EPI-743(一种苯醌类化合物)在细胞和动物模型中表现出显著减少氧化应激损伤的能力，为线粒体疾病治疗提供了实验依据。
(注：以上文献为示例，实际引用时需核实来源及准确性。)
**Background of EPI Recombinant Proteins**
Recombinant proteins, including EPI (Epidermal Growth Factor Pathway Inhibitor) recombinant proteins, are engineered using genetic modification techniques to express specific protein sequences in host systems like bacteria, yeast, or mammalian cells. EPI proteins are designed to modulate cellular signaling pathways, particularly those involving epidermal growth factor receptors (EGFR), which play critical roles in cell proliferation, survival, and differentiation. Dysregulation of EGFR signaling is linked to cancers, inflammatory diseases, and fibrosis, making EPI proteins a focus for therapeutic and research applications.
The development of EPI recombinant proteins stems from advancements in molecular biology and bioprocessing. By cloning the EPI gene into expression vectors, researchers achieve high-yield protein production, followed by purification to ensure biological activity and safety. These proteins are utilized in drug discovery, target validation, and as tools to study EGFR-related mechanisms.
EPI recombinant proteins offer advantages over traditional small-molecule inhibitors, including higher specificity and reduced off-target effects. They are also pivotal in personalized medicine, where tailored therapies target specific EGFR mutations. Additionally, their role extends to diagnostics, serving as antigens in assays to detect EGFR expression levels in patient samples.
In recent years, EPI-based biologics have entered preclinical and clinical trials, highlighting their potential in oncology and regenerative medicine. Challenges remain in optimizing stability, delivery, and cost-effectiveness, but ongoing innovations in protein engineering and scalable production methods continue to enhance their applicability. Overall, EPI recombinant proteins represent a versatile and evolving toolset in both therapeutic development and biomedical research.
×
